Background {#Sec1}
==========

Otitis media is an inflammation of the tympanic membrane and middle ear with a spectrum including acute otitis media, otitis media with effusion and chronic suppurative otitis media \[[@CR1], [@CR2]\]. Otitis media often occur secondary to acute upper respiratory tract infections, can also be caused by allergy and changes of the middle ear or Eustachian tube anatomically or functionally \[[@CR3]\]. Worldwide around 1.23 billion people are affected by otitis media, thus it is ranked as the fifth global burden of disease and the second cause of hearing loss \[[@CR2], [@CR4]\]. Children are the most affected groups and it is one of the commonest disease responsible for receiving antibiotics among children \[[@CR4]--[@CR6]\]. Otitis media is a major chronic disease in low and middle-income countries than in high-income countries. The highest incidence rate reported from Sub-Saharan Africa and South Asia \[[@CR4]--[@CR8]\].

Otitis media, especially with a chronic and recurrent form, is associated with complications such as hearing loss, decreased learning capability, and low educational achievement \[[@CR9]\]. Around 20,000 people, majorly children under 5 years of age, die every year with the associated complications \[[@CR7]\].

Majorly pathogenic bacteria such as non-typable *Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Proteus mirabilis, Escherichia coli,* and *Moraxella catarrhalis* are the etiological agents of otitis media \[[@CR10]--[@CR15]\], although viruses and fungi also associated \[[@CR14]--[@CR16]\]. The occurrence of otitis media is directly related to the colonization rate of the nasopharynx by the bacteria \[[@CR12]\]. Viral upper respiratory tract infections (URTI), disrupts the mucociliary system, impairs the host's primary mechanical defense for bacterial invasion and predispose children to acute otitis media (AOM) \[[@CR12]--[@CR15]\]. This study is aimed to quantitatively estimate the isolation rate of bacteria from patients with otitis media (OM), major isolates and resistance of isolates to commonly used antibacterial agents.

Methods {#Sec2}
=======

Study protocol {#Sec3}
--------------

Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) flow diagram \[[@CR17]\] was followed for identification of records, screening of titles and abstracts, and evaluation of full texts for inclusion. We have followed the PRISMA checklist \[[@CR18]\] throughout the review and the published methodology can be accessed from <http://www.crd.york.ac.uk/PROSPERO/display_record.php?> ID = CRD42018102485. The study protocol is also registered on PROSPERO with reference number ID: CRD42018102485.

Identification of records and search strategy {#Sec4}
---------------------------------------------

Legitimate databases and indexing services like PubMed/MEDLINE, EMBASE (Ovid interface), ScienceDirect and other supplementary sources, including Google Scholar, World Cat catalog, WHO African Index-Medicus and Cochrane library were visited to carry out the literature search. Relevant findings closely related to bacterial otitis media and isolation of agents were retrieved through advanced search strategies in major databases. HINARI: WHO for developing countries was used to access articles published in subscription-based journals under Science-Direct and Wiley online library. Indexing terms and carefully selected key-words were used to facilitate the search within the specified time (online records from 2009 to 2018). However, there is a deviation from the protocol published on PROSPERO, which stated from 2013 to 2018. The search was expanded back to 2009 to include more studies for subgroup analysis and to have a good pooled estimate. The time frame is set because antimicrobial resistance is a time-sensitive issue and is changing through time.

For systematic identification of records, keywords like Otitis Media \[MeSH\], Bacteria \[MeSH\], Africa South of the Sahara \[MeSH\], Otitis Media with Effusion \[MeSH\], Otitis Media, Suppurative \[MeSH\], "middle ear inflammation", "middle ear effusion", "secretory otitis media", "purulent otitis media" and each sub-Saharan country entry term with Boolean operators (AND, OR), and truncation were used. All articles available online until February 25 -- March 5, 2019, were considered. Google Scholar and World Cat were used to access gray literature from organizations and online university repositories. There was no language preference set in search strategy for all databases except for Google Scholar search, where the language preference was set to English and French. This deviation from the protocol (articles only English language) was made after observing some studies in the region that were published in the French language.

Screening and eligibility of studies {#Sec5}
------------------------------------

ENDNOTE version 8.0.1 (Thomson Reuters, Stamford, CT, USA) was used to manage the search results and to identify duplicate records. Records were also checked manually to avoid duplicates due to variation in reference styles across sources followed by a screening of titles and abstracts with predefined inclusion criteria. Two authors (TT and HM) independently evaluated the full texts of selected articles for eligibility and the discrepancies between the two authors' evaluations were solved by the other authors to come up with a consensus.

Inclusion and exclusion criteria {#Sec6}
--------------------------------

Patients with clinically confirmed otitis media were the study participants. Otitis media was defined as middle ear inflammation with discharge and without a clear indication of the tympanic membrane, and participants with middle ear inflammation with discharge for more than 3 months with a perforated tympanic membrane were considered as chronic suppurative otitis media. Records, published from 2009 to 2018, on the isolation of bacterial pathogens from ear swab or discharge, and susceptibility testing were included regardless of the patient's clinical characteristics.

Review and original articles conducted outside of sub-Saharan Africa were excluded during initial screening. Articles with data collection period before 2009, having unrelated, missing or insufficient outcomes, and irretrievable full texts (after requesting the corresponding authors) were excluded.

Data extraction {#Sec7}
---------------

Two authors (TT and HM) independently extracted important data related to study characteristics (country, first author, year of publication, study design, patient characteristics, number of culture-positive results (bacterial), nature of bacterial isolates, and number of isolates) and outcome of interest (number of culture-positive results, number of isolates with prevalence data for each bacterium, and susceptibility test results) using data abstraction format prepared in Microsoft Excel ([Data Extraction and Summary sheet](#MOESM1){ref-type="media"}).

Critical appraisal of studies {#Sec8}
-----------------------------

Critical appraisal to assess the internal (systematic error) and external (generalizability) validity of studies and to reduce the risk of biases was conducted according to the Joanna Briggs Institute's critical appraisal tool adapted for prevalence studies \[[@CR19]\] and graded out of 9 points. The mean score of the two authors was taken for final decision and studies with a score greater than or equal to five were included.

Outcome measurements {#Sec9}
--------------------

The primary outcome measure is the prevalence of bacterial otitis media, major isolates and the antimicrobial resistance in sub-Saharan Africa. The measurement regarding antimicrobial resistance was conducted for selected drugs (Ampicillin, Sulfamethoxazole-Trimethoprim (cotrimoxazole), Chloramphenicol, Amoxicillin-clavulanic acid, Gentamycin, Ceftriaxone, Cefuroxime, Erythromycin, Tetracycline, and Ciprofloxacin) obtained from patients with presumed or confirmed otitis media.

Data processing and statistical analysis {#Sec10}
----------------------------------------

Stata version 15 was used for analyses of outcome measures after importing data extracted in Microsoft excel format. We have applied the DerSimonian and Laird's random-effects model for the analyses at a 95% confidence level considering the variation in true effect sizes across the population (clinical heterogeneity). The heterogeneity of studies was determined using I^2^ statistics. A univariate meta-regression model was performed, with a cutoff value *p*-value\< 0.05, on study characteristics to assess the possible source of heterogeneity. Begg's and Egger's tests were used to evaluate the presence of publication bias, and presented with funnel plots of the standard error of proportions \[[@CR20], [@CR21]\].

Results {#Sec11}
=======

Search results {#Sec12}
--------------

We conducted a systematic review and Meta-analysis per under the PRISMA statement \[[@CR17]\]. In our literature search, a total of 1314 records were identified from several sources. From these, 621 duplicate articles were removed with the help of ENDNOTE and manual tracing. The remaining 693 records were screened using their titles and abstracts, and 607 of them were excluded. Eligibility evaluation of full texts was done for 86 records. From these, 32 articles were also excluded as the outcome of interest was missing, insufficient and/or ambiguous, and 2 articles were not accessible in full text \[[@CR22], [@CR23]\]. Fifty-two studies were evaluated by a full-text review and 16 studies had data collection period before 2009 and three studies \[[@CR24]--[@CR26]\] have no record of the data collection period. Finally, 33 articles passed the eligibility criteria and quality assessment and hence included in the study (Fig. [1](#Fig1){ref-type="fig"}). Thirty-two studies were utilized for the analysis of prevalence, one study has reported only the isolates without the prevalence of otitis media, and only 22 studies were utilized for the assessment of susceptibility testing since the other 11 studies have an incomplete report regarding study outcome and in some studies, the test was done with a variable number of isolates for different drugs. Fig. 1PRISMA flow diagram for Bacterial Otitis Media in sub-Saharan Africa

Study characteristics {#Sec13}
---------------------

As shown in Table [1](#Tab1){ref-type="table"}, a total of 33 studies with 6034 participants were included for systematic review and meta-analysis. Seven of the included studies were retrospective analyses of secondary data (record review) from regional laboratories and hospitals \[[@CR28], [@CR29], [@CR35], [@CR37], [@CR42], [@CR43], [@CR48]\]. Fourteen studies were conducted on chronic suppurative otitis media \[[@CR27], [@CR31], [@CR33], [@CR36], [@CR40]--[@CR42], [@CR45], [@CR48], [@CR50], [@CR53], [@CR54], [@CR56], [@CR58]\] and the rest included studies do not indicate the type of otitis media. Seven studies \[[@CR30], [@CR32], [@CR35], [@CR39], [@CR44], [@CR52], [@CR57]\] were conducted in children whereas the rest of the studies included patients of all age groups. The average quality scores of studies ranged from 5 to 8 as per the Joanna Briggs Institute scoring scale for prevalence studies (Table [1](#Tab1){ref-type="table"}). All studies have collected ear swab/discharge samples and applied standard microbiological culturing techniques for isolation of bacterial agents and followed the international standard for performing susceptibility testing and interpretation of results (CLSI standards). Concerning the country of study, 14 studies were from Nigeria, 8 studies from Ethiopia, 2 studies from Zambia, and a single study from Angola, South Africa, Sudan, Burkina Faso, Tanzania, Uganda, Ghana, and Malawi. Table 1Characteristics of studies describing the prevalence of bacterial otitis mediaSr.No.AuthorPositiveSample sizeCountryStudy designPopulation characteristicsYearQuality scoreNumber of isolatesType of sampleAge of participants1Afolabi OA et al. (2012) \[[@CR27]\]134.5135NigeriaCSpatients with CSOM20126138Ear discharge5-10 yrs. = 46; 11-20 yrs. = 26; 21-30 yrs. = 18; 31-40 yrs. = 20; 41-50 yrs. = 6; 51-60 yrs. = 10; 61-70 yrs. = 142Appiah-Korang L., et al. (2014) \[[@CR28]\]277315GhanaCS®patients with OM20135322Ear swab\<=1 yrs. = 64; 2-4 yrs. = 63; 5-13 yrs. = 55; 14-19 yrs. = 11; 20-44 yrs. = 53; 45-64 yrs. = 19; \> = 65 yrs. = 73Argaw-Denboba A et.al. (2014) \[[@CR29]\]10241225EthiopiaCS®patients with OM201481124Ear discharge\< 5 yrs. = 153; 5-15 yrs. = 253; 16-35 yrs. = 434; 36-50 yrs. = 105; \> = 51 = 474Chidozie AH et al. (2015) \[[@CR30]\]137156NigeriaCSpediatric patients with OM20147152Ear discharge\<=5 yrs. = 1375Chirwa M., et al. (2015) \[[@CR31]\]116118MalawiCSpatients with CSOM20138214Ear discharge\< 18 yrs. = 64; \> = 18 yrs. = 406Ejiofor S. O., et al. (2016) \[[@CR32]\]3040NigeriaCSpediatric patients with OM2015743Ear swab\<=1 yrs. = 22; 2-4 yrs. = 8; 5-7 yrs. = 5; 8-9 yrs. = 57Elmustafa M., et al. (2016) \[[@CR33]\]204217SudanCSpatients with CSOM20135305Ear discharge\< 16 yrs. = 90; 16-30 yrs. = 50; 31-45 yrs. = 37; 46-60 yrs. = 31; \> 60 yrs. = 88Fayemiwo SA et.al. (2017) \[[@CR34]\]9198NigeriaCSpatients with OM20176115Ear discharge\< 10 yrs. = 54; 11-20 yrs. = 8; 21-30 yrs. = 20; 31-40 yrs. = 4; 41-50 yrs. = 3; \> 50 yrs. = 99Garba B. I., et al. (2017) \[[@CR35]\]4353NigeriaCS®pediatric patients with OM2017545Ear swab0--5 yrs. = 38; 5--10 yrs. = 10; 10-15 yrs. = 510Habibu A. (2015) \[[@CR36]\]68.569NigeriaCSpatients with CSOM2013568Ear discharge0 -- 5 yrs. = 14; 6-11 yrs. = 12; 12-17 yrs. = 8; 18-23 yrs. = 1; 24-29 yrs. = 3; 30-35 yrs. = 0; 36-41 yrs. = 0; \> 41 yrs. = 111Hailu D., et al. (2016) \[[@CR37]\]296368EthiopiaCS®patients with OM20155296Ear discharge0-10 yrs. = 91; 11-20 yrs. = 102; 21-30 yrs. = 51; 31-40 yrs. = 31; 41-50 yrs. = 17; 51-60 yrs. = 3; \> 61 yrs. = 112Jido BA et al. (2014) \[[@CR38]\]95110NigeriaCSPatients with OM2011695Ear swab0-5 yrs. = 61; 6-10 yrs. = 14; 11-15 yrs. = 5;\> = 16 yrs. = 613Jik A et al. (2015) \[[@CR39]\]154182NigeriaCSpediatric patients with OM20157154Ear swab1-3 yrs. = 59; 4-6 yrs. = 47; 7-9 yrs. = 30; 10-12 yrs. = 1814Justin R et al. (2018) \[[@CR40]\]89.590UgandaCSpatients with CSOM20165127Ear discharge\< 18 yrs. = 47; \> 18 yrs. = 4215Kazeem M. J. and R. Aiyeleso (2016) \[[@CR41]\]360380NigeriaCSpatients with CSOM20155371Ear discharge\< 10 yrs. = 256; 11-20 yrs. = 72; 21-30 yrs. = 26; 31-40 yrs. = 15; 41-50 yrs. = 3; 51-60 yrs. = 7; \> 60 yrs. = 116Matundwelo N. and C. Mwansasu (2016) \[[@CR42]\]60.561ZambiaCS®patients with CSOM20166154Ear discharge0-7 yrs. = 34; 8-15 yrs. = 2617Muluye D et al. (2013) \[[@CR43]\]204228EthiopiaCS®patients with OM20137204Ear discharge0-5 yrs. = 51; 6-10 yrs. = 31; 11-15 yrs. = 17; 16-20 yrs. = 21; 21-30 yrs. = 45; 31-40 yrs. = 21; \> = 41 yrs. = 1818Nwogwugwu, NU et al. (2014) \[[@CR44]\]128152NigeriaCSpediatric patients with OM20146128Ear dischargeno age specific data19Ogah S. and J. Ogah (2016) \[[@CR45]\]8896NigeriaCSpatients with CSOM20135149Ear discharge0-10 yrs. = 34; 11-20 yrs. = 28; 21 = 30 yrs. = 16; 31-40 yrs. = 12; 41-50 yrs. = 8; 51-60 yrs. = 6; 61-70 yrs. = 2; 71-80 yrs. = 420Ohieku, J. and F. Fakuade (2013) \[[@CR46]\]107125NigeriaCSPatients with OM20105117Ear swab0-2 yrs. = 49; 2-5 yrs. = 20; 6-12 yrs. = 9; 13-18 yrs. = 4; 19-64 yrs. = 24; \> = 65 yrs. = 121Onifade AK et al. (2018) \[[@CR47]\]NigeriaCSPatients with OM20155537Ear discharge22Orji F. T. and B. O. Dike (2015) \[[@CR48]\]202206NigeriaCS®patients with CSOM20135250Ear discharge\< 1 yrs. = 12; 1-5 yrs. = 37; 5-15 yrs. = 58; \> 15 yrs. = 9923Ouedraogo RW et al. (2012) \[[@CR49]\]3441Burkina FasoCSpatients with OM2012536Ear swabno age specific data24Phiri H., et al. (2016) \[[@CR50]\]98100ZambiaCSpatients with CSOM20165169Ear discharge\<=5 yrs. = 19; 6-10 yrs. = 7; 11-15 yrs. = 7; 16-20 yrs. = 15; 21-25 yrs. = 7; 26-30 yrs. = 13; 31-35 yrs. = 6; 36-40 yrs. = 8; 41-45 yrs. = 5; 46-50 yrs. = 5; 51-55 yrs. = 2; 61-65 yrs. = 1; 66-70 yrs. = 525Seid A et al. (2014) \[[@CR51]\]171191EthiopiaCSpatients with OM20107207Ear discharge\< 5ys = 33; 5-9 yrs. = 18; 10-14 yrs. = 35; 15-19 yrs. = 32; 20-24 yrs. = 20; 25-29 yrs. = 17; 30-34 yrs. = 7; 35-39 yrs. = 10; 40-44 yrs. = 6; 45-49 yrs. = 4; \> = 50 yrs. = 926Tiedt NJ et al. (2013) \[[@CR52]\]8086South AfricaCSpediatric patients with OM20136153Ear discharge\< 13 yrs. = 8627Udden F., et al. (2018) \[[@CR53]\]150152AngolaCSpatients with CSOM20165443Ear discharge\< 5 yrs. = 34; 5-9 yrs. = 23; 10-14 yrs. = 24; \> = 15 yrs. = 55; no age data = 1628Wasihun A. G. and Y. Zemene (2015) \[[@CR54]\]157162EthiopiaCSpatients with CSOM20158216Ear discharge0-5 yrs. = 30; 6-10 yrs. = 41; 11-15 yrs. = 22; 16-20 yrs. = 11; 21-25 yrs. = 23; 26-30 yrs. = 9; \> 30 yrs. = 2629Worku S., et al. (2017) \[[@CR55]\]154167EthiopiaCSpatients with OM20147171Ear discharge\< 15 yrs. = 60; 15-40 yrs. = 81; \> 40 yrs. = 2630Adoga AA et al. (2011) \[[@CR56]\]^a^7597NigeriaCSpatients with CSOM2009575Ear discharge1-10 yrs. = 40; 11-20 yrs. = 23; 21-30 yrs. = 16; 31-50 yrs. = 11; \> 50 yrs. = 731Hailegiyorgis TT et al. (2018) \[[@CR57]\]^a^95196EthiopiaCSpediatric patients with OM2014795Ear swab\< 2 yrs. = 41; 2-4 yrs. = 36; \> 4-5 yrs. = 1832Mushi M. F., et al. (2016) \[[@CR58]\]^a^126301TanzaniaCSpatients with CSOM2014660Ear discharge1-10 yrs. = 31; 11-20 yrs. = 52; 21-30 yrs. = 51; 31-40 yrs. = 59; 41-50 yrs. = 55; \> 50 yrs. = 3333Worku M. and M. Bekele (2014) \[[@CR59]\]^a^61117EthiopiaCSpatients with OM2013669Ear swabChildren = 53; Adult = 64*CS* cross-sectional, *CS®* Retrospective cross-sectional, *OM* Otitis Media, *CSOM* Chronic Suppurative Otitis Media^a^Studies removed from analysis of pooled prevalence by sensitivity analysis

Study outcome measures {#Sec14}
----------------------

### Prevalence of bacterial otitis media {#Sec15}

The overall estimate of bacterial isolation was 92% (95% CI: 90.0, 94.0) with a degree of heterogeneity (I^2^), 93.77%. A change was observed on the degree heterogeneity after excluding the known outliers and, performing subgroup analysis and sensitivity testing based on the type of otitis media and age group. The highest bacterial isolation rate was obtained among patients with chronic suppurative otitis media (CSOM) (98%) with a 66.91% degree of heterogeneity. Among patients with otitis media with inclusion of all age groups the prevalence was 87% (I^2^ = 74.13%) and among pediatric patients with otitis media 86% (I^2^ = 53.66%) (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Frost plot depicting bacterial Otitis Media in sub-Saharan Africa

After a univariate meta-regression analysis, the year of study, country of study, study design, and sample size were not found to be statistically significant, however, the type of otitis media was found to be significant (*p*-value = 0.001).

Bacterial isolates {#Sec16}
------------------

From all bacterial isolates, the commonest isolate was *Pseudomonas* species (majorly *P. aeruginosa*) (ranging from 23 to 25% across subgroups) followed by *S. aureus* (18--27%), *Proteus* species (mainly *P. mirabilis*), *Klebsiella* species, Coagulase Negative *Staphylococci* (CoNS) and *Streptococcus* species like *S. pyogenes*, and *Enterococcus* species. Other gram-negative rods under the *Enterobacteriaceae* (*Citrobacter* species, *Providencia* species, *Serratia* species, *Enterobacter* species, and *Morganella* species) account for 7--11%, but separately they account for less than 5% (Table [2](#Tab2){ref-type="table"}, and [Data Extraction and Summary sheet: *isolates*](#MOESM1){ref-type="media"}). On the subgroup analysis, *S. aureus* was found to be the major isolate except for chronic suppurative otitis media and *Streptococcus* species were observed to have a relatively higher prevalence in pediatric patients with otitis media (Table [2](#Tab2){ref-type="table"}). Table 2Subgroup analysis of bacterial isolates by type of otitis mediaBacterial isolateType of otitis media, prevalence % (95% CI)Patients with CSOMPatients with OMPediatric patients OMPooled prevalence (%)No of studyI^**2**^ (%)Pooled prevalence (%)No of studyI^**2**^ (%)Pooled prevalence (%)No of studyI^**2**^ (%)*S. aureus*18(11--25)1496.223(19--27)1288.2927(15--39)794.9CoNS7(2--12)482.59(4--14)696.981(0--5)1*Streptococcus* spp5(3--7)1079.182(1--4)870.7910(4--15)582.7*Pseudomonas* spp23(18--29)1492.4724(18--29)1293.9525(16--33)788.33*Proteus* spp19(15--22)1281.0019(14--23)1289.6811(5--18)690.29*E. coli*9(6--11)1388.047(3--10)1194.068(5--11)757.47*Klebsiella* spp12(9--16)1291.157(5--10)1191.015(1--9)482.95Other Enterobacteriaceae10(2--17)595.7311(6--17)692.317(1--14)3*S. pneumoniae*3 (1--6)488.292 (1--4)592.876 (3--9)439.46*H. influenzae*2 (0--3)21 (0--3)18(5--11)2

Four studies have demonstrated the isolation of *Acinetobacter* species, and *Corynebacterium* species were isolated by two studies. Anaerobic bacteria were not commonly isolated from the studies, but a study by Chirwa M et al \[[@CR31]\] has reported the isolation of *Bacteroides* species and *Peptostreptococcus* species.

Though the main objective of this review is bacterial etiologies we found out that fungal pathogens like *Candida* species and *Aspergillus* species account for 6% (3--8%) of the etiology for otitis media; only one study has indicated *Aspergillus* species.

The resistance of isolates to antibacterial agents {#Sec17}
--------------------------------------------------

Studies have included various drugs for susceptibility testing. We have selected drugs that have been tested in more than 5 studies and accordingly, the analysis was done for Ampicillin, Cotrimoxazole, Cefuroxime, Amoxicillin*-*clavulanate, Ciprofloxacin, Gentamycin, Chloramphenicol, Amoxicillin, Ceftriaxone, Tetracycline, and Erythromycin.

A higher degree of pooled resistance was observed in Ampicillin (72%, ranging from 69 to 94% across subgroups), Amoxicillin (68, 62--85%), Cotrimoxazole (60, 41--90%), Amoxicillin*-*clavulanic acid (54, 47--61%), and Cefuroxime (51, 17--64%) and. The lowest degree of resistance was found among Ciprofloxacin, Gentamycin, and Chloramphenicol (Table [3](#Tab3){ref-type="table"}, and [Data Extraction and Summary sheet: *susceptibility*](#MOESM1){ref-type="media"}). Generally, a higher degree of resistance was observed in pediatric patients with otitis media than the other subgroups. Table 3Subgroup analysis of drug resistance by type of otitis mediaBacterial isolateType of otitis media, prevalence % (95% CI)Patients with CSOMPatients with OMPediatric patients OMPooled prevalence (%)No of studyI^**2**^ (%)Pooled prevalence (%)No of studyI^**2**^ (%)Pooled prevalence (%)No of studyI^**2**^ (%)Ampicillin70(54--86)898.5669(48--90)799.0994(91--98)2Cotrimoxazole63(47--80)798.0341(11--72)699.5890(78--100)3Amoxicillin------62(37--87)598.7885(81--89)2Ceftazidime52(28--76)497.097(1--16)357(47--66)1Chloramphenicol32(21--48)895.9825(13--38)697.8755(45--64)1Ciprofloxacin19(12--25)1094.3616(9--24)694.2334(12--56)3Gentamycin23(15--31)1196.5426(13--40)698.2555(34--75)492.92Amoxicillin- Clavulanic acid53(32--74)798.7647(8--86)499.4861(13--100)499.59Erythromycin41(16--66)698.9138(6--71)599.4381(68--93)3Cefuroxime64(60--69)217(14--20)260(27--93)498.08Ceftriaxone32(18--46)897.7318(10--26)591.7175(58--92)492.19Tetracycline37(10--63)498.8520(6--35)398(88--100)1

Publication bias {#Sec18}
----------------

There is some evidence of publication bias in studies reporting the prevalence of bacterial isolates as confirmed by funnel plots of the standard error with proportion supplemented by statistical tests (Begg's test, *p* = 0.0016; Egger's test, *p* = 0.0211) (Fig. [3](#Fig3){ref-type="fig"}). However, there was no significant publication bias in the subgroup analysis. Fig. 3Funnel plot depicting publication bias for Bacterial Otitis Media in sub-Saharan Africa

Discussion {#Sec19}
==========

This analysis included 32 original studies addressing bacterial isolation rate from otitis media within the specified time-frame. Since all the included studies have a cross-sectional study design the pooled analysis could be used to assess the relative importance of various pathogens in Africa as well as worldwide. All the included studies in this review have collected an ear swab/discharge sample for microbiological analysis. The bacterial isolation rate using culture-based techniques ranged from 86% (pediatric patients) to 98% (patients with CSOM). Data coverage was featuring predominantly within some countries like Nigeria while most other countries don't have any study to represent the population.

Bacteria can reach the middle ear in otitis media from nasopharynx through the Eustachian tube or from the external ear canal through the non-intact eardrum. Aerobic bacteria like *S. aureus*, *P. aeruginosa* and *Proteus* species (majorly *P. mirabilis*) were the main bacterial pathogens for otitis media in this analysis. The finding of those pathogens as a major isolate provides a more definitive confirmation of what has been reported by other published single-country studies as the result consistent \[[@CR37], [@CR41], [@CR45]\]. Other bacteria are also indicated from studies like *Klebsiella* species (6--11%), CoNS (6--12%), and *E. coli* (5--9%).

The prevalence of other pathogens like *H. influenzae*, *S. pneumoniae* and, *M. catarrhalis* is very minimal, even though those isolates were indicated from another review \[[@CR60], [@CR61]\], and commonly reported from AOM and OME episodes, especially during childhood \[[@CR4], [@CR12], [@CR14]\]. Since most of the studies conducted in sub-Saharan Africa are on CSOM and the collected samples are ear swab/discharge these pathogens are less likely to be reported from the studies. This minimal finding could also be due to regional differences or the absence of studies conducted using molecular techniques that had higher sensitivity compared to culture techniques.

On a recent international consensus on the management of otitis media with effusion panelists generally agreed not to consider antibiotics as a non-surgical management option for OME \[[@CR62]\]. Several other reviews have indicated that the management of OM is far better with antibiotics and oto-topical agents than without any treatment, especially if it is CSOM \[[@CR63], [@CR64]\]. Considering this review setting and population, treatment with antibiotics is a primary option as most of the studies are conducted on patients with CSOM. On the contrary, isolates from otitis media were having a high level of resistance to commonly used antibacterial agents in this analysis. The highest resistance is against ampicillin (ranging from 69 to 94%) followed by Amoxicillin (62--85%), cotrimoxazole (41--90%), Augmentin (47--61%) and Cefuroxime (17--64%). Generally, the resistance to erythromycin, ceftriaxone, Tetracycline, and ceftazidime was less than 50% for most of the studies. Those drugs are commonly used drugs for the management of otitis media, especially in low-income country settings without appropriate microbiological diagnostic service. This review also found that relatively higher susceptibility of isolates to ciprofloxacin, gentamycin, and chloramphenicol, less than 35% resistance. The studies included in this review revealed that non-susceptibility to fluoroquinolones ranged between 16 and 34%.

All studies in this review span on the analysis of ear swab/ discharge, which is a late-onset scenario. Early diagnosis and management of otitis media have a paramount effect on the health of the patients, especially children, as it has complications ranging from tympanic membrane perforation to neurological impairments. Early-onset infections will require the collection of middle ear fluid by tympanocentesis, which will be hard to practice in sub-Saharan Africa, without advanced medical facilities. A clear contribution of pathogens, like fastidious and anaerobic bacteria, can be understood by using highly sensitive laboratory techniques.

It is unlikely that this review has missed a relevant study as we have conducted a highly sensitive systematic search, including grey literature. The dearth of appropriate population-based elegant studies, risk of bias in prevalence studies, mainly due to under-reporting; and heterogeneity of data were the main limitations of this review. Etiological data were more consistent with some discrepancies in isolation rates, which can be explained by the quality of the microbiological procedures used, such as sample collection and transportation and bacterial isolation in some studies. One of the recognized limitations in such pooled studies \[[@CR65]\] is differences in middle ear fluid collection guidelines in different localities even with efforts to standardize the design across studies. There are likely differences in care-seeking practices for OM among countries, affecting the severity of cases, and one country may collect middle ear fluid only in cases considered to be recurrent OM. The true contribution of these bacteria to OM is likely higher than the reported as bacterial etiology was not determined by molecular techniques in the included studies \[[@CR66]\]. Different clinical severity or age tropisms may have been observed from culture-negative samples with molecular testing.

Following accepted methods, all-inclusive searching with date range, put together with a quality appraisal of the included studies are the main strength of this review. Stakeholders who focus on such matters will get a great benefit from compiling all available evidence to make informed decisions on prevention measures.

Conclusions {#Sec20}
===========

The analysis revealed that *P. aeruginosa, S. aureus* and *P. mirabilis* are the commonest bacterial pathogens responsible for otitis media in sub-Saharan Africa. A high level of resistance was observed to commonly used antibacterial agents such as Ampicillin, cotrimoxazole, Amoxicillin, and Amoxicillin-clavulanate however, isolates were less resistant to Ciprofloxacin, Gentamycin, and Chloramphenicol.

Thus, drugs like Ampicillin, amoxicillin, Amoxicillin-clavulanate, and cotrimoxazole should not be used as a first-line treatment in sub-Saharan countries since countries in this geographical location are commonly dependent on clinical data for treatment with the absence of microbiology laboratory. Without proper treatment, otitis media could lead to intracranial and intratemporal complications with higher and complex management.
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**Additional file 1:**Data extraction and summary sheet. **Sheet 1 (character):** participant information and culture positive rate of Otitis media. **Sheet 2 (isolates):** Bacterial isolates from Otitis media. **Sheet 3 (susceptibility):** Drug susceptibility test of isolates.
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